Nakashima Koki, Demura Yoshiki, Tada Toshihiko, Ishizuka Tamotsu
Department of Respiratory Medicine, University of Fukui, Fukui, JPN.
Department of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Fukui, JPN.
Cureus. 2024 Aug 9;16(8):e66537. doi: 10.7759/cureus.66537. eCollection 2024 Aug.
This is a long-term follow-up case report of a 71-year-old man with lung adenocarcinoma and choroidal metastasis harboring an epidermal growth factor receptor mutation. Blurry vision, caused by the choroidal metastasis, improved with first-line treatment with afatinib. Thereafter, osimertinib was administered as a second-line treatment, then chemotherapy containing pemetrexed plus bevacizumab as a third-line treatment. For 61 months, recurrence of choroidal metastasis was absent. Only a few reports of lung cancer with choroidal metastasis provide long-term follow-up of more than five years. Therefore, the clinical course of this patient may provide some insights for long-term management in such cases.
这是一例71岁肺腺癌伴脉络膜转移且携带表皮生长因子受体突变患者的长期随访病例报告。脉络膜转移引起的视力模糊在一线使用阿法替尼治疗后有所改善。此后，奥希替尼作为二线治疗药物，然后培美曲塞联合贝伐单抗的化疗作为三线治疗。在61个月的时间里，脉络膜转移未复发。仅有少数关于肺癌伴脉络膜转移的报告提供了超过五年的长期随访。因此，该患者的临床病程可能为这类病例的长期管理提供一些见解。
